Startups
April Six makes moments that matter for the brands that shape the future. We meet the unique marketing and communications requirements of brands in Mobility, Technology and Science through our deep, specialist knowledge of these core industries. Located in London, Harefield, Bournemouth, Munich, San Francisco, Seattle and Singapore.
Overview
Location
Canada, Ontario, Toronto
Employees
51-200
Phone
+44 1895 825599
Founded date
2000
Mentions in press and media 11
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Feb 16, 2023 | Pharming provides update on EMA regulatory review of leniolisib for APDS in Europe | EMA Marketing Authorisation Application for leniolisib changed to standard review timetable LEIDEN, Netherlands, Feb. 16, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM)... |
| Dec 15, 2022 | Pharming announces positive interim analysis data from open-label extension study of leniolisib in presentation at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition | V. Koneti Rao, MD, shared new evidence of long-term safety and hematologic response in patients who received leniolisib to treat APDS, a rare primary immunodeficiency Interim analysis demonstrated leniolisib to be well tolerated and indicat... |
| Dec 7, 2022 | Pharming announces publication of data from Phase 3 Study of leniolisib in patients with APDS in ASH's Blood | Leniolisib was well tolerated and significant improvement over placebo was notable in the co-primary endpoints, reflecting a favorable impact on patients' immune dysregulation and deficiency The peer-reviewed publication heightens internati... |
| Oct 28, 2022 | Pharming Announces European Medicines Agency (EMA) Validates its Marketing Authorisation Application under Accelerated Assessment for leniolisib | Marketing authorisation in the European Economic Area anticipated in H1 2023 LEIDEN, Netherlands, Oct. 28, 2022 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM / Nasdaq: PHAR)... |
| Oct 11, 2022 | Pharming submits a Marketing Authorisation Application to the European Medicines Agency for Leniolisib | Application is based on randomized, controlled and long-term extension data for leniolisib as a treatment for APDS, a rare primary immunodeficiency This submission follows the grant of accelerated assessment allowing an expedited review for... |
| Sep 28, 2022 | Pharming Announces US FDA Acceptance for Priority Review of its New Drug Application for Leniolisib | The FDA has assigned a PDUFA goal date of March 29, 2023 for the NDA submission based on randomized-controlled and long-term extension data for leniolisib as a treatment for APDS, a rare primary immunodeficiency LEIDEN, The Netherlands, Sep... |
| Sep 26, 2022 | SOMAÍ Pharmaceuticals Opens Portugal Manufacturing Facility | LISBON, Portugal, Sept. 26, 2022 (GLOBE NEWSWIRE) -- SOMAÍ Pharmaceuticals Unipessoal LDA has officially opened its new state-of-the-art pharmaceutical EU-GMP facility in Portugal. SOMAÍ’s phase 1 manufacturing footprint spans 3,800 square ... |
| Aug 19, 2022 | At Artificial General Intelligence (AGI) Conference, DRLearner is Released as Open-Source Code -- Democratizing Public Access to State-of-the-Art Software for AI/Machine Learning | SEATTLE, Aug. 19, 2022 /PRNewswire/ -- The 15th annual Artificial General Intelligence (AGI) Conference opens today at Seattle's Crocodile Venue. Running from August 19-22, the AGI conference event includes in-person events, live streaming,... |
| Apr 1, 2022 | Pharming Announces Positive Data from Phase II/III Leniolisib Trial Presented at Clinical Immunology Society 2022 Annual Meeting | LEIDEN, Netherlands, April 1, 2022 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces new data from the pivotal Phase II/III trial of leniolisib for the t... |
Show more
Reviews 0
FAQ about April Six
When was April Six founded?
April Six was founded in 2000.
What has the press written about April Six?
Parsers VC has collected 11 articles mentioning April Six, among them “Pharming provides update on EMA regulatory review of leniolisib for APDS in Europe” (Feb 16, 2023) and “Pharming announces positive interim analysis data from open-label extension study of leniolisib in presentation at the 64th American Society of Hematology (A...” (Dec 15, 2022).
Is April Six still active?
Yes, April Six is active; its latest activity on Parsers VC dates from Dec 15, 2022.